Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Buspirone/Zolmitriptan - Contera Pharma

Next Previous
Drug Profile

Buspirone/Zolmitriptan - Contera Pharma

Alternative Names: AV-2860; JM-010

Latest Information Update: 19 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Contera Pharma
  • Developer Bukwang Pharmaceutical; Contera Pharma
  • Class Antidepressants; Antimigraines; Antiparkinsonians; Anxiolytics; Oxazolidinones; Pyrimidines; Small molecules; Spiro compounds; Tryptamines
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Dopamine modulators; Neurotransmitter agents; Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Drug-induced dyskinesia

Most Recent Events

  • 17 Jan 2024 Phase-II clinical trials in Drug-induced dyskinesia in Slovakia, South Korea (PO)
  • 17 Jan 2024 Safety and pharmacodynamics data from a preclinical studies in drug induced dyskinesia released by Contera pharma
  • 30 Nov 2022 Korean Ministry of Food and Drug safety approves IND application for JM 010 in dyskinesia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top